US House Drug Pricing Bill Amended To Target Launch Prices, Set For Swift Advance
Executive Summary
House Speaker Pelosi’s amended HR 3 expands scope of targeted drugs, adds manufacturer transparency requirements ahead of dual markups and a hearing on 17 October.